Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 1: Infliximab and Adalimumab

Statistics

Review article

Uso de Fármacos Biológicos en Dermatosis Fuera de la Indicación Aprobada. Primera parte: Infliximab y Adalimumab

B. Díaz-Ley

Corresponding author

blancadiazley@hotmail.com

Correspondence: Servicio de Dermatología, Hospital Universitario de La Princesa, Diego de León, 62, 28006 Madrid, Spain.

, G. Guhl, J. Fernández-Herrera

Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, Spain

Read

8910

Times
was read the article

3477

Total PDF

5433

Total HTML

Share statistics

Article information

ISSN: 15782190
Original language: English

DOI:10.1016/S1578-2190(07)70539-5

The statistics are updated each day

Year/Month	Html	Pdf	Total

2025 6	60	13	73
2025 5	168	36	204
2025 4	188	36	224
2025 3	125	27	152
2025 2	108	35	143
2025 1	87	27	114
2024 12	58	21	79
2024 11	92	52	144
2024 10	84	55	139
2024 9	63	44	107
2024 8	104	78	182
2024 7	65	49	114
2024 6	64	51	115
2024 5	67	34	101
2024 4	52	43	95
2024 3	65	51	116
2024 2	49	42	91
2024 1	48	40	88
2023 12	49	23	72
2023 11	49	35	84
2023 10	44	44	88
2023 9	61	27	88
2023 8	45	38	83
2023 7	35	70	105
2023 6	44	69	113
2023 5	43	22	65
2023 4	29	20	49
2023 3	46	39	85
2023 2	28	30	58
2023 1	37	23	60
2022 12	35	41	76
2022 11	26	30	56
2022 10	32	22	54
2022 9	29	43	72
2022 8	33	51	84
2022 7	23	36	59
2022 6	18	36	54
2022 5	44	48	92
2022 4	49	48	97
2022 3	38	52	90
2022 2	32	28	60
2022 1	33	39	72
2021 12	20	40	60
2021 11	43	49	92
2021 10	43	49	92
2021 9	30	48	78
2021 8	48	32	80
2021 7	46	28	74
2021 6	36	28	64
2021 5	22	25	47
2021 4	51	45	96
2021 3	66	25	91
2021 2	52	38	90
2021 1	41	30	71
2020 12	23	21	44
2020 11	34	19	53
2020 10	17	13	30
2020 9	39	19	58
2020 8	45	21	66
2020 7	26	19	45
2020 6	43	21	64
2020 5	25	20	45
2020 4	28	18	46
2020 3	42	29	71
2020 2	1	3	4
2020 1	0	4	4
2019 12	0	12	12
2019 11	0	9	9
2019 10	0	3	3
2019 9	0	7	7
2019 8	0	3	3
2019 7	0	18	18
2019 6	0	15	15
2019 5	0	41	41
2019 4	0	4	4
2019 3	0	5	5
2019 2	0	3	3
2019 1	0	4	4
2018 12	0	1	1
2018 9	0	5	5
2018 8	0	17	17
2018 7	0	6	6
2018 6	0	16	16
2018 5	0	13	13
2018 4	0	13	13
2018 3	2	6	8
2018 2	25	9	34
2018 1	21	8	29
2017 12	24	13	37
2017 11	24	8	32
2017 10	22	11	33
2017 9	23	13	36
2017 8	27	12	39
2017 7	26	7	33
2017 6	36	42	78
2017 5	31	17	48
2017 4	27	14	41
2017 3	21	13	34
2017 2	18	10	28
2017 1	23	13	36
2016 12	48	12	60
2016 11	45	12	57
2016 10	64	14	78
2016 9	72	20	92
2016 8	71	16	87
2016 7	47	10	57
2016 6	12	13	25
2016 5	6	14	20
2016 4	5	14	19
2016 3	3	8	11
2016 2	7	6	13
2016 1	5	3	8
2015 12	12	3	15
2015 11	10	4	14
2015 10	7	2	9
2015 9	10	10	20
2015 8	8	2	10
2015 7	52	1	53
2015 6	43	7	50
2015 5	94	19	113
2015 4	71	11	82
2015 3	50	11	61
2015 2	63	9	72
2015 1	58	25	83
2014 12	55	6	61
2014 11	31	9	40
2014 10	37	17	54
2014 9	42	14	56
2014 8	42	20	62
2014 7	48	20	68
2014 6	45	15	60
2014 5	64	15	79
2014 4	40	8	48
2014 3	44	26	70
2014 2	38	19	57
2014 1	38	25	63
2013 12	41	23	64
2013 11	29	18	47
2013 10	36	24	60
2013 9	35	36	71
2013 8	47	31	78
2013 7	46	63	109
2013 6	36	39	75
2013 5	34	32	66
2013 4	32	36	68
2013 3	52	28	80
2013 2	24	15	39
2013 1	14	9	23

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter